Mothe, Andrea J.
Tassew, Nardos G.
Shabanzadeh, Alirezha P.
Penheiro, Romeo
Vigouroux, Robin J.
Huang, Lili
Grinnell, Christine
Cui, Yi-Fang
Fung, Emma
Monnier, Philippe P.
Mueller, Bernhard K.
Tator, Charles H.
Article History
Received: 30 May 2017
Accepted: 17 August 2017
First Online: 5 September 2017
Competing Interests
: Mabs AE12-1 and AE12-1Y were developed by AbbVie and are the property of this company. The company owns all the rights and commercial interests on the use of these antibodies. L.H., C.G., Y.-F.C., E.F., and B.K.M. are employees of AbbVie. Financial support for this research was provided in part by AbbVie. AbbVie participated in the analyses of the antibody concentrations and in the review and approval of the manuscript. C.H.T. is a member of the Department of Surgery, University of Toronto, and has received personal compensation for consulting and serving on scientific advisory boards from AbbVie.